Intelligent OMICS, a biotechnology firm specialising in harnessing artificial intelligence (AI) for expediting drug discovery, has unveiled a significant target discovery partnership with Janssen Research & Development, a subsidiary of the Janssen Pharmaceutical Companies under Johnson & Johnson.
This collaboration will unite Intelligent OMICS' exclusive AI platform, which amalgamates multi-omics data with sophisticated deep learning algorithms to unveil previously undiscovered disease mechanisms and potential therapeutic avenues for treatment. It will integrate seamlessly with Janssen's proficiency in data science, oncology research, and development.
As per the agreement's provisions, Intelligent OMICS will receive an initial payment and research assistance from Janssen, in addition to prospective milestone payments contingent upon the successful development of products resulting from this joint endeavour.
The collaboration holds the promise of unearthing fresh insights into the molecular underpinnings of haematological cancers and the identification of novel targets for treatment. This could pave the way for the creation of innovative and more efficacious therapies tailored to combat these complex diseases.
Dr. Robert Grundy, CEO of Intelligent OMICS, expressed his enthusiasm for this partnership with Janssen, highlighting that haematological cancers pose some of the most formidable and intricate challenges in the realm of treatment. He stated, "We believe that our AI platform can generate novel insights into the molecular drivers of these cancers and identify new ways to intervene therapeutically."
This partnership underscores the capacity of AI to expedite drug discovery and underscores the dedication of both entities to advancing novel cancer treatments.
The collaborative effort is anticipated to span a duration of three years.
Click here to read the original news story.